Ozmosi | BBT-001 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

BBT-001

Alternative Names: BBT-001, BBT 001, BBT001
Clinical Status: Active
Latest Update: 2026-01-06
Latest Update Note: News Article

Product Description

Mechanisms of Action: IL31 Inhibitor, IL4 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanzhuyao (Beijing) Biopharmaceutical Technology Co., Ltd.
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BBT-001

Countries in Clinic: Australia, China, New Zealand, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Dermatitis, Atopic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06808477

 BBT001-001

P1

Recruiting

Dermatitis, Atopic

2026-08-21

12%

2025-11-13

Patient Enrollment|Primary Endpoints

NCT07239947

 BBT001-002

P1

Recruiting

Dermatitis, Atopic

2026-08-31

2025-11-21

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

01/06/2026

News Article

 Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

09/25/2025

News Article

 Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001

05/30/2025

News Article

 Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001

02/28/2025

News Article

 Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions